ARO-MMP7 / Arrowhead, Sarepta Therap - LARVOL DELTA

Study of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients With Idiopathic Pulmonary Fibrosis (clinicaltrials.gov) - P1/2 | N=97 | Recruiting | Sponsor: Arrowhead Pharmaceuticals | Trial completion date: Mar 2025 ➔ Sep 2025 | Trial primary completion date: Mar 2025 ➔ Sep 2025

Trial completion date • Trial primary completion date • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases • MMP7

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics (Businesswire) - "Arrowhead Pharmaceuticals, Inc...today announced that the global licensing and collaboration agreement with Sarepta Therapeutics (NASDAQ: SRPT) announced on November 26, 2024, has now closed. Closing of the transaction was subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary conditions...Upon closing, Arrowhead receives a $500 million upfront payment and $325 million through the purchase by Sarepta of Arrowhead common stock priced at $27.25 per share. Arrowhead will also receive $250 million to be paid in annual installments of $50 million over 5 years...ARO-HTT for patients Huntington’s disease expected to be CTA-ready in 2025; ARO-ATXN1 for patients with spinocerebellar ataxia 1 (SCA1) expected to be CTA-ready in 2026; ARO-ATXN3 for patients with spinocerebellar ataxia 3 (SCA3) expected to be CTA-ready in 2026."

IND • Licensing / partnership • Ataxia • Huntington's Disease • Idiopathic Pulmonary Fibrosis • Muscular Dystrophy • Myotonic Dystrophy

Arrowhead Pharmaceuticals Announces Global License and Collaboration Agreement with Sarepta Therapeutics for Multiple Clinical and Preclinical Programs (Businesswire) - "Arrowhead Pharmaceuticals, Inc...announced a global licensing and collaboration agreement with Sarepta Therapeutics (NASDAQ: SRPT). Upon closing, Arrowhead will receive $825 million, consisting of $500 million cash and $325 million as an equity investment priced at a 35% premium....Summary of Programs under License and Collaboration Agreement...ARO-MMP7, which is designed to reduce expression of matrix metalloproteinase 7, or MMP7, in the lung as a potential treatment for idiopathic pulmonary fibrosis, currently dosing patients in a Phase 1/2 clinical study."

Licensing / partnership • Idiopathic Pulmonary Fibrosis • Pulmonary Disease

Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars (Businesswire) - "Arrowhead Pharmaceuticals, Inc...announced its plan to host a 2024 Summer Series of R&D webinars that highlight multiple clinical stage RNA interference (RNAi) based medicines that utilize the company’s proprietary Targeted RNAi Molecule (TRiMTM) platform. Each webinar in the Summer Series will focus on a specific therapeutic area and will feature presentations by Arrowhead team members about the company’s clinical candidates and external key opinion leaders, who will discuss the respective disease areas and treatment landscapes....Pulmonary – ARO-RAGE, ARO-MUC5AC, ARO-MMP7; Date: July 16, 2024."

Clinical • Idiopathic Pulmonary Fibrosis • Pulmonary Disease • Respiratory Diseases

ARO-MMP7: Initiation of P2 trial for IPF in 2024 (Arrowhead, 42nd Annual J.P. Morgan Healthcare Conference)

New P2 trial • Idiopathic Pulmonary Fibrosis

ARO-MMP7: Initiation of P2 trial for IPF in 2024 (Arrowhead, 42nd Annual J.P. Morgan Healthcare Conference)

New P2 trial • Idiopathic Pulmonary Fibrosis

Study of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients With Idiopathic Pulmonary Fibrosis (clinicaltrials.gov) - P1/2 | N=97 | Recruiting | Sponsor: Arrowhead Pharmaceuticals | Trial completion date: Aug 2024 ➔ Mar 2025 | Trial primary completion date: Aug 2024 ➔ Mar 2025

Trial completion date • Trial primary completion date • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

A clinical-stage RNAi therapeutic candidate for IPF mediates durable MMP7 silencing in nonhuman primates and human lung tissue (ERS 2023) - "Previous work established that lung-targeted MMP7 siRNAs effectively limit fibrosis and improve function in a rat bleomycin injury model. ARO-MMP7, currently in Phase 1/2a trials for the treatment of IPF, effectively silenced BAL MMP7 protein expression in nonhuman primates for over 2 weeks following a single inhaled dose and similarly reduced MMP7 expression in human PCLS, highlighting the value of ex vivo systems for translational validation of siRNA drugs.; Physiology; Pulmonary function testing; Cell and molecular biology; Imaging"

Clinical • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Inflammation • MMP7

Study of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients With Idiopathic Pulmonary Fibrosis (clinicaltrials.gov) - P1/2 | N=77 | Recruiting | Sponsor: Arrowhead Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases • MMP7

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MMP7 for Treatment of Idiopathic Pulmonary Fibrosis (Businesswire) - "Arrowhead Pharmaceuticals Inc...announced today that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-MMP7, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce the expression of matrix metalloproteinase 7 (MMP7) as a potential treatment for idiopathic pulmonary fibrosis (IPF)....AROMMP7-1001...is a Phase 1/2a single ascending dose and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-MMP7 in up to 56 healthy volunteers and up to 21 patients with IPF."

Trial status • Idiopathic Pulmonary Fibrosis • Pulmonary Disease • Respiratory Diseases

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2022 Earnings Call Transcript (Yahoo Finance) - "ARO-MMP7 is designed to the reduce expression of matrix metalloproteinase 7, or MMP7, as a potential treatment for idiopathic pulmonary fibrosis, or IPF. MMP7 is thought to play multiple roles in IPF pathogenesis, including promoting inflammation and aberrant epithelial repair and fibrosis. Silencing MMP7 expression in a rat IPF model reduced inflammatory cell infiltration, limited lung fibrosis, and preserved pulmonary function. In August, we filed a CTA to begin a Phase 1/2 clinical study of ARO-MMP7. The Phase 1/2 study will be similar in design to our other first in human studies and includes a healthy volunteer portion followed by a patient portion."

New P1/2 trial • Idiopathic Pulmonary Fibrosis • Interstitial Lung Disease

Study of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients With Idiopathic Pulmonary Fibrosis (clinicaltrials.gov) - P1/2 | N=77 | Not yet recruiting | Sponsor: Arrowhead Pharmaceuticals

New P1/2 trial • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases • MMP7